(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 October 2010 (21.10.2010)

PCT

(10) International Publication Number
WO 2010/121225 A3

(51) International Patent Classification:

A61K 31/4375 (2006.01)	*A61P 33/02* (2006.01)
A61K 31/519 (2006.01)	*A61P 35/02* (2006.01)
A61P 31/16 (2006.01)	*A61P 31/12* (2006.01)
A61P 25/00 (2006.01)	*A61P 25/28* (2006.01)
A61P 29/00 (2006.01)	*A61P 25/16* (2006.01)
A61P 7/00 (2006.01)	*A61P 31/18* (2006.01)
A61P 21/00 (2006.01)	*A61P 31/22* (2006.01)

(21) International Application Number:
PCT/US2010/031520

(22) International Filing Date:
16 April 2010 (16.04.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/170,468	17 April 2009 (17.04.2009)	US
61/240,165	4 September 2009 (04.09.2009)	US
61/242,227	14 September 2009 (14.09.2009)	US
61/297,669	22 January 2010 (22.01.2010)	US

(71) Applicant *(for all designated States except US)*: **CYLENE PHARMACEUTICALS, INC.** [US/US]; 5820 Nancy Ridge Drive, Suite 200, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HADDACH, Mustapha** [US/US]; 14744 Via Mantova, San Diego, CA 92127 (US). **O'BRIEN, Sean** [GB/US]; 2958 Emerald Place, Carlsbad, CA 92009 (US). **ANDERES, Kenna** [US/US]; 5522 Mill Creek Road, San Diego, CA 92130 (US).

(74) Agent: **WU, Nan**; Cooley LLP, 777 6th Street, NW, Suite 1100, Washington, DC 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

[Continued on next page]

(54) Title: METHOD OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY

(I)



(57) Abstract: The invention provides methods for the treatment or amelioration of disorders associated with undesired activity of protein kinase CK2, using compounds of Formula (I) that are potent, selective inhibitors of CK2, and pharmaceutical compositions of such compounds, wherein Z^5, R^{6B}, R^{6D}, R^8, n, R^9 and p are defined as further described herein,

WO 2010/121225 A3

(88) Date of publication of the international search report:
6 January 2011